Tarceva - tarceva.com : Tarceva® (erlotinib) Tablets for Advanced-Stage NSCLC & Advanced-Stage Pancreatic Cancer

3.03 Rating by ClearWebStats

tarceva.com is 2 decades 2 years 11 months old. This website has a #3,172,473 rank in global traffic. It has a .com as an domain extension. This website has a Google PageRank of 4 out of 10. This domain is estimated value of $ 240.00 and has a daily earning of $ 1.00. It is also listed in Dmoz. While no active threats were reported recently by users, tarceva.com is SAFE to browse.

Updated 9 years 10 months ago

Get Custom Widget

Traffic Report of Tarceva

Daily Unique Visitors:	152
Daily Pageviews:	304

Estimated Valuation

Income Per Day:	$ 1.00
Estimated Worth:	$ 240.00

Search Engine Indexes

Google Indexed Pages:	Not Applicable
Yahoo Indexed Pages:	Not Applicable
Bing Indexed Pages:	11

Search Engine Backlinks

Google Backlinks:	Not Applicable
Bing Backlinks:	16
Alexa BackLinks:	70

Safety Information

Google Safe Browsing:	No Risk Issues
Siteadvisor Rating:	No Risk Issues
WOT Trustworthiness:	Good
WOT Privacy:	Good
WOT Child Safety:	Excellent

Website Ranks & Scores

Google Pagerank:
Alexa Rank:	3,172,473
Domain Authority:	42 ON 100

Google Pagerank

PR 4 out of 10

PageSpeed Score

Siteadvisor Rating

No Risk Issues

Where is tarceva.com server located?

Hosted IP Address:

72.34.128.212

Hosted Country:

Location Latitude:

33.1959

Location Longitude:

-117.379

Social Engagement

Facebook Shares:	16
Facebook Likes:	Not Applicable
Facebook Comments:	1
Twitter Count (Tweets):	Not Applicable
Linkedin Shares:	Not Applicable
Delicious Shares:	Not Applicable

Page Resources Breakdown

Homepage Links Analysis

Page Title of Tarceva

Tarceva® (erlotinib) Tablets for Advanced-Stage NSCLC & Advanced-Stage Pancreatic Cancer

Meta Description of Tarceva

Discover Tarceva® (erlotinib) Tablets, a treatment for advanced-stage non-small cell lung cancer (NSCLC) and advanced-stage pancreatic cancer. Who is Tarceva for? Tarceva is approved as a first-line treatment, maintenance treatment, and second- or third-line treatment for advanced-stage non-small cell lung cancer (NSCLC).Tarceva is prescribed as initial treatment for patients with NSCLC whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. (First-line treatment). Tarceva is prescribed as maintenance treatment for advanced-stage NSCLC in patients whose cancer has not spread or grown after prior treatment with certain types of chemotherapy. Tarceva is prescribed as second- or third-line treatment for advanced-stage NSCLC in patients whose cancer has spread or grown after receiving at least one round of chemotherapy. Tarceva is not meant to be used at the same time as certain types of chemotherapy for advanced NSCLC. For initial treatment of patients with NSCLC whose cancer has spread to other parts of the body, it is not known if Tarceva is safe and effective in other EGFR mutations. Tarceva is approved for advanced-stage pancreatic cancer. Tarceva in combination with gemcitabine is prescribed for patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy. Important Safety Information: What is the most important information I should know about Tarceva? Everyone reacts differently to treatment with Tarceva. Some people may have side effects, while others may not. It’s important to know the most common and serious side effects with Tarceva. Your healthcare provider (HCP) may lower the dose or stop treatment with Tarceva if any serious side effects occur. Contact your HCP right away if you experience any of the following side effects. What are the possible side effects of Tarceva? Tarceva can cause serious side effects, which include: Interstitial lung disease, or ILD, events. Tarceva has been shown to cause lung problems, including death. Symptoms of lung problems may include shortness of breath, cough, and fever. Tarceva may need to be stopped if you have any of these symptoms. Liver and kidney problems. Tarceva has been shown to cause severe kidney and liver problems, including death. Some people had their kidneys and liver stop working. Let your HCP know if you have a history of liver or kidney disease. Gastrointestinal (GI) perforation. Tarceva has been shown to cause GI perforation, a hole that develops in your stomach or intestine, which has led to death. People taking Tarceva at the same time as medications that may help block the growth of blood vessels, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), or certain chemotherapies or those who have a history of ulcers or other stomach disease may be at higher risk of perforation. Serious skin conditions. Tarceva has been shown to cause blistering and skin peeling. This may result in other serious skin disorders or death. Blood, bleeding, and clotting problems. Tarceva has been shown to cause certain blood problems and other bleeding and clotting problems. These have led to heart attack, stroke, and death. Eye disorders. Tarceva has been shown to cause eye irritation and damage to the cornea. Tarceva may also cause unusual eyelash growth or swelling of the cornea. This swelling may irritate the eye or cause damage. Bleeding events when taking warfarin with Tarceva. Tell your HCP if you are taking a blood thinner, such as warfarin, or non-steroidal anti-inflammatory drugs, known as NSAIDs. Taking Tarceva with these medications can cause death. Pregnancy. Tarceva can cause harm an unborn baby. Do not breast-feed when taking Tarceva. Women should use effective birth control during treatment and for at least 2 weeks after the last dose of Tarceva. Contact your HCP if you have become pregnant or if pregnancy is suspected, during treatment with Tarceva. When should I call my HCP while taking Tarceva? Serious or ongoing diarrhea, nausea (feeling sick to your stomach), loss of appetite, or vomiting. New or worsening shortness of breath or cough. Eye irritation. New or worsening rash, blistering, or peeling of the skin. Any changes in smoking habits. What are some of the most common side effects? First-line NSCLC treatment: Diarrhea, weakness, rash, cough, shortness of breath, and loss of appetite. Maintenance/Second- or third-line NSCLC treatment: Rash and diarrhea. Pancreatic cancer treatment: Fatigue (feeling tired), rash, nausea, loss of appetite, and diarrhea. What should I know about skin (including rash), hair and nail problems or diarrhea while taking Tarceva? Skin (including rash): Your skin may look red with little bumps. It may look like acne, but is not. The rash most commonly occurs on the face, upper chest, and back, but it could spread to other parts of the body and may start peeling. It could happen or get worse if the skin is exposed to the sun. You may feel itching, tenderness, or burning. When taking Tarceva, you may see skin and nail darkening or dry skin, with or without cracking. This most often occurs with rash. While taking Tarceva, you may want to use alcohol-free lotions and sunscreens or avoid being out in the sun. In Tarceva clinical trials, rash was treated with steroids or antibiotics. Using acne medicines may dry your skin and make the rash worse. The treatment of rash has not been studied. Talk with your HCP if you notice a rash. He or she may be able to help you manage it. Hair and nails: Hair and nail problems have been seen in patients taking Tarceva, such as abnormal hairiness and brittle or loose nails. Diarrhea: Diarrhea can usually be treated by anti-diarrhea medicine. Your HCP can help you find the right medicine for you. What should I do if I am taking or am prescribed other medicines or supplements while taking Tarceva? It is important to tell your HCP about all of the medicines and herbal supplements you are taking. DO NOT start taking any new medicines or herbal supplements before talking with your HCP. DO NOT eat grapefruit or drink grapefruit juice while taking Tarceva, except under the care of your HCP. Will smoking affect my treatment with Tarceva? If you smoke, you should stop smoking before starting treatment with Tarceva. If you continue to smoke, your treatment with Tarceva may need to be adjusted. Talk to your HCP. Call your HCP for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.Please see full Product Information at www.tarceva.com for additional important safety information.

Website Inpage Analysis

H1 Headings:	1	H2 Headings:	11
H3 Headings:	19	H4 Headings:	Not Applicable
H5 Headings:	Not Applicable	H6 Headings:	Not Applicable
Total IFRAMEs:	Not Applicable	Total Images:	22
Google Adsense:	Not Applicable	Google Analytics:	UA-6139881-1

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Expires: Sun, 19 Nov 1978 05:00:00 GMT
Last-Modified: Fri, 23 May 2014 06:03:56 0000
Cache-Control: no-cache, must-revalidate, post-check=0, pre-check=0
ETag: "1400825036"
Content-Language: en
Link: ; rel="canonical",; rel="shortlink"
Content-Type: text/html; charset=utf-8
Content-Length: 62065
Accept-Ranges: bytes
Date: Fri, 23 May 2014 06:27:06 GMT
X-Varnish: 45245178
Age: 0
Connection: close
X-Cache: MISS

Domain Information for tarceva.com

Domain Registrar:	GODADDY.COM, LLC
Registration Date:	2001-05-04 2 decades 2 years 11 months ago
Last Modified:	2013-07-25 1 decade 8 months 4 weeks ago
Expiration Date:	2015-05-04 8 years 11 months 2 weeks ago

Domain Nameserver Information

Host		IP Address	Country
dnadns1e.gene.com		72.34.128.76	United States
dnadns2e.gene.com		72.34.128.76	United States

DNS Record Analysis

Host	Type	TTL	Extra
tarceva.com	A	3580	IP:72.34.128.212
tarceva.com	NS	3600	Target:dnadns2e.gene.com
tarceva.com	NS	3600	Target:dnadns3e.gene.com
tarceva.com	NS	3600	Target:dnadns4e.gene.com
tarceva.com	SOA	3600	MNAME:bc-dns-ext-mstr.gene.com RNAME:postmaster.no.email.please Serial:404592124 Refresh:3600 Retry:600 Expire:2592000
tarceva.com	MX	3600	Priority:10 Target:smtaextvv02.gene.com
tarceva.com	MX	3600	Priority:10 Target:smtaextrwc01.gene.com
tarceva.com	MX	3600	Priority:10 Target:smtaextrwc02.gene.com
tarceva.com	MX	3600	Priority:10 Target:smtaextvv01.gene.com